Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 11/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 8/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.42 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.42 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957032 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL4421181 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL188081 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL4419214 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL4421189 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL23391696 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL4420457 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL20641484 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| Hydrochloric Acid SCHEMBL23391711 | 0.98 | SLC7A5 (0.56) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| Hydrochloric Acid SCHEMBL23391697 | 0.98 | SLC7A5 (0.56) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | claimed |
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | claimed |
| WO-2024245407-A1 | CONJUGATES AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-12-05 | — | — | WO | claimed |
| US-20240247034-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH INC (US) | 2024-07-25 | — | — | US | claimed |
| EP-4380620-A2 | PHOTOREACTIVE ANTIBODY BINDING DOMAINS WITH EPITOPE TAGS FOR MULTIPLEXED ANTIBODY LABELING, DETECTION, AND PURIFICATION | The Trustees of The University of Pennsylvania (US) | 2024-06-12 | — | — | EP | claimed |
| CN-116365044-A | Electrolyte, secondary battery and electric equipment | 欣旺达电动汽车电池有限公司 | 2023-06-30 | — | — | CN | claimed |
| US-20230174596-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH INC (US) | 2023-06-08 | — | — | US | claimed |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-04-13 | — | — | US | claimed |
| US-20220372022-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-11-24 | — | — | US | claimed |
| WO-1999046272-A1 | SERINE PEPTIDASE MODULATORS | FONDATECH BENELUX N.V. (BE) | 1999-09-16 | — | — | WO | claimed |
| US-5939458-A | APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN | GILLETTE COMPANY, THE | 1999-08-17 | — | — | US | claimed |
| WO-1999015136-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 1999-04-01 | — | — | WO | claimed |
| US-5744331-A | AEROBIC FERMENTATION OF BACTERIA BELONGING TO THE GENUS ESCHERICHIA | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1998-04-28 | — | — | US | claimed |
| US-5543396-A | Proline phosphonate derivatives | GEORGIA TECH RESEARCH CORP. (US) | 1996-08-06 | — | — | US | claimed |
| CN-1127787-A | Method for producing L-leucine | KYOWA HAKKO KOGYO KK (JP) | 1996-07-31 | — | — | CN | claimed |
| US-5514694-A | ENZYME INHIBITORS | GEORGIA TECH RESEARCH CORP (US) | 1996-05-07 | — | — | US | claimed |
| EP-0698668-A1 | Process for producing L-leucine | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-02-28 | — | — | EP | claimed |
| WO-1995029691-A1 | PROLINE PHOSPHONATE DERIVATIVES | GEORGIA TECH RESEARCH CORPORATION (US) | 1995-11-09 | — | — | WO | claimed |
| US-4421854-A | MUTANT OF ARTHROBACTER | W. R. GRACE & CO. (US) | 1983-12-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | SLC7A5 1166/4885SLC1A2 2114/4885SLC1A1 2654/4885 |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | TST, ABAT, AADAC | SLC7A5 378/4885SLC1A2 1423/4885SLC1A1 786/4885 |
| US-20220372022-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | DNPEP, NPEPPS, PAM | SLC7A5 1166/4885SLC1A2 2114/4885SLC1A1 2654/4885 |
| US-20240247034-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | LRP6, LDLR, KDR | SLC7A5 504/4885SLC1A2 1497/4885SLC1A1 1129/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | SLC7A5 64/4885SLC1A2 271/4885SLC1A1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.